Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 5/20 | 0.59 |
| ▸ | SRC | P12931 | 5/20 | 0.59 |
| ▸ | KIT | P10721 | 8/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | STAT1 | P42224 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3322150 | 0.90 | ABL1 (0.61) | ABL1SRCKITSMN1; SMN2NPC1 | |
| SCHEMBL3322938 | 0.87 | BRAF (0.57) | KITSMN1; SMN2NPC1TP53STAT1 | |
| SCHEMBL3319309 | 0.84 | ABL1 (0.62) | ABL1SRCKITSMN1; SMN2NPC1 | |
| SCHEMBL5269648 | 0.82 | KIT (0.56) | KITSMN1; SMN2NPC1TP53STAT1 | |
| SCHEMBL2986376 | 0.79 | KIT (0.48) | KITSMN1; SMN2NPC1TP53STAT1 | |
| SCHEMBL4476666 | 0.78 | ABL1 (0.63) | ABL1SRCKITSMN1; SMN2ALDH1A1 | |
| SCHEMBL3322959 | 0.78 | ABL1 (0.56) | ABL1SRCKITSMN1; SMN2NPC1 | |
| SCHEMBL2986377 | 0.77 | BTK (0.60) | ABL1SRCKITRAB9AALDH1A1 | |
| SCHEMBL3318931 | 0.77 | KIT (0.52) | ABL1SRCKITRAB9AMEN1 | |
| SCHEMBL4465811 | 0.77 | KIT (0.57) | ABL1SRCKITNPC1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101208339-B | Heterocyclic benzylamino derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN LA ROCHE | 2010-12-29 | — | — | CN | claimed |
| US-7776878-B2 | Heterocyclic benzylamino derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2010-08-17 | — | — | US | claimed |
| US-20100120840-A1 | Heterocyclic benzylamino derivatives, their manufacture and use as pharmaceutical agents | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-13 | — | — | US | claimed |
| CN-101208339-A | Heterocyclic benzylamino derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2008-06-25 | — | — | CN | claimed |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2021-08-19 | — | — | US | disclosed |
| CN-112755193-A | Method of treating malignancies with anti-tyrosine kinase inhibitors using dianhydrogalactitol or a derivative thereof | 德玛医药 | 2021-05-07 | — | — | CN | disclosed |
| EP-2872161-B1 | DIANHYDROGALACTITOL FOR USE IN TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS | DEL MAR PHARMACEUTICALS (CA) | 2020-12-16 | — | — | EP | disclosed |
| US-20150182490-A1 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2015-07-02 | — | — | US | disclosed |
| EP-2872161-A2 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | Del Mar Pharmaceuticals (CA) | 2015-05-20 | — | — | EP | disclosed |
| WO-2014004376-A2 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | DEL MAR PHARMACEUTICALS (CA) | 2014-01-03 | — | — | WO | disclosed |
| CN-101208339-B | Heterocyclic benzylamino derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN LA ROCHE | 2010-12-29 | — | — | CN | disclosed |
| US-7776878-B2 | Heterocyclic benzylamino derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20100120840-A1 | Heterocyclic benzylamino derivatives, their manufacture and use as pharmaceutical agents | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-13 | — | — | US | disclosed |
| CN-101208339-A | Heterocyclic benzylamino derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2008-06-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150182490-A1 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | WHR1, AIPL1, TDP1 | ABL1 698/4885SRC 1484/4885KIT 4462/4885 |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DCLRE1B, AIPL1, WHR1 | ABL1 746/4885SRC 1586/4885KIT 4492/4885 |
| US-20100120840-A1 | Heterocyclic benzylamino derivatives, their manufacture and use as pharmaceutical agents | CYP3A5, ABCB1, CYP3A43 | ABL1 442/4885SRC 2766/4885KIT 555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.